Uchida H, Nakakita Y, Enoki N, Abe N, Nakamura T, Munekata M
Pharmaceutical Research Laboratories, Sapporo Breweries Ltd., Shizuoka, Japan.
J Antibiot (Tokyo). 1994 Jun;47(6):648-54. doi: 10.7164/antibiotics.47.648.
Three novel antibiotics, named chrymutasins A, B and C, were isolated from the fermentation products of a mutant strain obtained by NTG (N-methyl-N'-nitro-N-nitrosoguanidine) treatment. The mutant strain produced the chrymutasins, which differed in the aglycone moiety from chartreusin, and related compounds. The production of these compounds needed a characteristically long fermentation period. The antitumor activity of chrymutasin A is better in vivo than that of chartreusin, the cytotoxic activity against cell lines in vitro is equivalent, and the antimicrobial spectrum is narrower.
从经N-甲基-N'-硝基-N-亚硝基胍(NTG)处理获得的突变菌株的发酵产物中分离出三种新型抗生素,分别命名为金霉素A、B和C。该突变菌株产生的金霉素在苷元部分与黄绿青霉素及相关化合物不同。这些化合物的产生需要一段特别长的发酵期。金霉素A在体内的抗肿瘤活性优于黄绿青霉素,在体外对细胞系的细胞毒性活性相当,且抗菌谱更窄。